Oncology Learning Network· @OncLearnNetwork · X·· 1 day agoScore70
Body · original
As presented at #ESMO2026, perioperative #durvalumab plus neoadjuvant enfortumab vedotin significantly improved survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based therapy.
Learn more: https://www.hmpgloballearningnetwork.com/site/onc/news/volga-trial-demonstrates-significant-survival-benefit-durvalumab-plus-enfortumab
43 views · 0 likes · 1 repost · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Oncology Learning Network · x.com